Considering strong preclinical data, clinical trials were developed in the first decade of the 2000s for adults with both R/R CD22+ BCP-ALL and B-cell non-Hodgkin lymphoma (B-NHL). This evidence concerns the gene OPN1SW and acute lymphoblastic leukemia.